R848 (Resiquimod) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-?, IL-6 and IFN-?. R848 is being developed for HCV infection treatment [1], as vaccine adjuvants [2], and as combined cancer immunotherapy agent [3]
Technical information:
| Chemical Formula: | C17H22N4O2 | |
| CAS #: | 144875-48-9 | |
| Molecular Weight: | 314.38 | |
| Purity: | > 98% | |
| Appearance: | White | |
| Chemical Name: | 1-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol | |
| Solubility: | Up to 50 mM in DMSO | |
| Synonyms: | Resiquimod, S28463; VML-600 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder or DMSO solution at -20oC desiccated.
Reference:
| 1. | Rockros PJ, et al. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 2007; 47(2): 174-182 Pubmed ID: doi.org/10.1016/j.jhep.2007.02.025 |
| 2. | Risini D, et al. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005; 23(45): 5263-5270 Pubmed ID: doi.org/10.1016/j.vaccine.2005.06.024 |
| 3. | Block MS, et al. A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1. Melanoma Res. 2019; 29(4): 420-427 Pubmed ID: 30520800 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.